Lorenza Burzi (L Burzi)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 13

Top Topics

Hidradenitis Suppurativa

Top Venues

Journal of the European Academy of Dermatology and Venereology : JEADV

Dermatologic therapy

International journal of dermatology

This page only lists publications with an associated author ORCID identifier.

Publications

Luca Mastorino, Paolo Dapavo, Lorenza Burzi, Francois Rosset, Isotta di Giunipero di Corteranzo, Francesco Leo, Anna Verrone, Elena Stroppiana, Michela Ortoncelli, Simone Ribero, Pietro Quaglino
Drug survival, effectiveness, and safety of brodalumab for moderate-to-severe psoriasis over up to 3 years. International journal of dermatology (2024)
Luca Mastorino, Paolo Dapavo, Lorenza Burzi, Francois Rosset, Isotta Giunipero di Corteranzo, Francesco Leo, Anna Verrone, Elena Stroppiana, Michela Ortoncelli, Simone Ribero, Pietro Quaglino
Drug survival, effectiveness, and safety of brodalumab for moderate-to-severe psoriasis up to 3 years. International journal of dermatology (2024)
Luca Mastorino, Paolo Dapavo, Lorenza Burzi, Francois Rosset, Isotta Giunipero di Corteranzo, Francesco Leo, Anna Verrone, Elena Stroppiana, Michela Ortoncelli, Simone Ribero, Pietro Quaglino
Drug survival, effectiveness, and safety of brodalumab for moderate-to-severe psoriasis up to 3 years. International journal of dermatology 63 (7) (2024)
Luca Mastorino, P Dapavo, Lorenza Burzi, F Rosset, I Giunipero di Corteranzo, F Leo, A Verrone, E Stroppiana, M Ortoncelli, Simone Ribero, Pietro Quaglino
Drug survival, effectiveness and safety of ixekizumab for moderate-to-severe psoriasis up to 5 years. Journal of the European Academy of Dermatology and Venereology : JEADV 38 (3) (2023)
Luca Mastorino, P Dapavo, Lorenza Burzi, F Rosset, I Giunipero di Corteranzo, F Leo, A Verrone, E Stroppiana, M Ortoncelli, Simone Ribero, Pietro Quaglino
Drug survival, effectiveness and safety of ixekizumab for moderate-to-severe psoriasis up to 5 years. Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
Luca Mastorino, P Dapavo, Lorenza Burzi, F Rosset, I Giunipero di Corteranzo, F Leo, A Verrone, E Stroppiana, M Ortoncelli, Simone Ribero, Pietro Quaglino
Drug survival, effectiveness and safety of ixekizumab for moderate-to-severe psoriasis up to 5 years. Journal of the European Academy of Dermatology and Venereology : JEADV 38 (3) (2023)
Giuseppe Gallo, Lorenza Burzi, Francesca Torrelli, Pietro Quaglino, Simone Ribero
Low-dose oral minoxidil in female patients with lichen planopilaris: Real-life experience. Journal of the European Academy of Dermatology and Venereology : JEADV (2022)
Gabriele Roccuzzo, Giulia Rozzo, Lorenza Burzi, Federica Repetto, Paolo Dapavo, Simone Ribero, Pietro Quaglino
Switching from adalimumab originator to biosimilars in hidradenitis suppurativa: What's beyond cost-effectiveness? Dermatologic therapy 35 (11) (2022)
Lorenza Burzi, Federica Repetto, Simone Ribero, Luca Mastorino, Pietro Quaglino, Paolo Dapavo
Paradoxical psoriasiform reactions during treatment with adalimumab for hidradenitis suppurativa: Real-life experience and therapeutic response to other biological drugs. Dermatologic therapy (2022)
Michele Parietti, Lorenza Burzi, Simone Ribero, Giuseppe Gallo, Federica Repetto, Paolo Dapavo
Persistent eruptive lentiginosis in a psoriatic patient after 4-year effective treatment with ustekinumab. Dermatologic therapy 35 (6) (2022)
Lorenza Burzi, Michele Parietti, Andrea Agostini, E Marra, M T Fierro, Simone Ribero, Pietro Quaglino
Eyelashes poliosis as first sign of metastatic melanoma. Journal of the European Academy of Dermatology and Venereology : JEADV 35 (7) (2021)
Federica Repetto, Lorenza Burzi, Alice Ramondetta, Giulia Rozzo, Matteo Licciardello, Simone Ribero, Pietro Quaglino, Paolo Dapavo
Certolizumab pegol and its role in pregnancy-age hidradenitis suppurativa. International journal of dermatology (2021)
Lorenza Burzi, Federica Repetto, Alice Ramondetta, Giulia Rozzo, Matteo Licciardello, Simone Ribero, Pietro Quaglino, Paolo Dapavo
Guselkumab in the treatment of severe hidradenitis suppurativa, a promising role? Dermatologic therapy 34 (3) (2021)